In Liverpool 🇬🇧 this week we hosted a discussion on the upcoming @UN General Assembly high-level meeting on #AMR and Liverpool's role in the global effort to address the crisis. With @InstituteGC, @GwynneMP & @wellcometrust 🇺🇳 Read about it on our blog 👇 https://t.co/fHRzVlLmp5

This unique analysis combines pharmacokinetics and pathogen genomics to explore the relative contribution of these factors to clinical outcomes from HIV-associated cryptococcal meningitis. @APTlivuni @JRPerfectID @KatharineStott https://t.co/O0Pi03bcg1

Bayesian Estimation of AMR prevalence (BEAR) is an algorithm to improve population infection management decisions (e.g. antimicrobial formularies, IPC policy) by enabling more precise & resource-efficient estimation of AMR prevalence https://t.co/jLppOKKj5K @AIex_Howard #JACNews

You can find out more about @livuni's important #AMR work here ➡️ https://t.co/ihcL7uczNC @APTlivuni @LivUniHLS @CAMO_Net1

Existing pre-clinical models don't adequately measure antimicrobial resistance in a way that readily translates to a clinical setting. Here, we sought to develop one. 7/n

Doses of antibiotics are generally optimised to produce optimal bacterial killing effect. However, the effect of resistance emerging to these agents is not just not taken into account; it is typically not even characterised as part of the drug development process. 2/n

This is the fundamental root cause of all antibiotic resistance. We use antibiotics at a dose that kills the bacteria enough to treat an infection, but not to suppress the resistance that emerges (either in the infection or elsewhere in the body) 3/n

This is especially a problem in pneumonia. These infections have a large volume of infective material with large numbers of bacteria, which are high enough that natural rates of genetic mutation provides opportunity for mechanisms of antimicrobial resistance to develop. 4/n

This happens even with newer agents. In the clinical trials for testing meropenem-vaborbactam and cefidercol for HAP, whilst both produced a successful trial outcome, emergence of resistance to both was seen in each trial. https://t.co/c6Komo2qlQ https://t.co/ChsPlDeTLk 6/n

This is particularly true for hospital-acquired pneumonia (HAP), which are caused more often by Gram-negatives (with P. aeruginosa being a common cause), which have a greater propensity to develop resistance on treatment. 5/n

It is a pleasure to announce the publication of our paper characterising the pharmacodynamics of emergent antimicrobial resistance to meropenem in pneumonia caused by Pseudomonas aeruginosa in mBio. 1/n https://t.co/1iQlWuYomc

Here, we developed PBPK models for fosfomycin and amikacin in neonates and used it to assess the predicted efficacy of these agents for the treatment of neonatal sepsis. @APTlivuni @LivuniIcat

Antimicrobial Pharmacology PhD #LivUniGrad @APTlivuni

Happening tonight @LymmFestival - The Science of Stranger Things with Prof Carsten Welsch @livuniphysics @cockcroft_news

Yesterday, our network gathered in Liverpool to celebrate our unique global partnership, which works towards addressing the many complex problems surrounding antimicrobial resistance #AMR @Wellcome_AMR @SouthAfricanASP

Pro Vice Chancellor of @livuniHLS spoke about the importance of Liverpool’s expertise in pharmacology and infectious diseases as a key element of our network

And Chibuzor Uchea, Research Manager in Drug Resistant Infections @wellcometrust expressed the urgent need to address AMR and how proud he is to support CAMO-Net.

We are so excited to bring you all of the latest AMR news and events from around the world so make sure to follow @CAMO_Net1 so we can keep in touch!

Alex Howard @AIex_Howard at #PintOfScience giving a wonderful talk about AI and UTI as part of #CAMONet @livuniHLS and @Wellcome_AMR . Clear, innovative and very engaging with great questions from the audience about sharing data, accountability and finding new ways to tackle #AMR

We are looking for a legal expert(s) who can help us write a review of the current statutes that govern data flows for #AMR for both individual and population health benefit. If you are interested can you DM me or @AIex_Howard